Actively Recruiting
Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma
Led by First People's Hospital of Hangzhou · Updated on 2023-02-21
70
Participants Needed
1
Research Sites
178 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A median survival period of 3 to 6 months is the prognosis for patients with advanced, unresectable EHCC. For patients with locally advanced, unresectable EHCC, effective management of tumor growth is the only option to increase stent patency and survival time. In patients with cholangiocarcinoma, photodynamic therapy (PDT) is therapy that has been shown to improve stent patency and overall survival (OS). Endoscopic radiofrequency ablation (RFA) has been demonstrated in numerous studies to prolong the life spans of individuals with malignant biliary obstruction . In the literature, comparing the clinical efficacy and adverse outcomes of these two endoscopic procedures is rare.
CONDITIONS
Official Title
Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed cholangiocarcinoma
- Unresectable cholangiocarcinoma due to local infiltration of major vessels confirmed by CT, MRCP, or EUS
- No previous treatment for cholangiocarcinoma
- Adequate bone marrow and organ function: white blood cells >4.0^9/L, hemoglobin >90 g/L, platelets >75^9/L, serum creatinine <2.0 mg/dl
- Karnofsky performance status score 65
- Signed written informed consent
You will not qualify if you...
- Imaging shows distant metastasis in liver, lung, or other organs
- Presence of other malignant tumors
- Pregnant or nursing women
- Previous gastrointestinal diversion surgery
- Participation in another study within one month before enrollment
- Alcohol or substance abuse or poor compliance as judged by a doctor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China, 310006
Actively Recruiting
Research Team
J
Jianfeng Yang, Doctor
CONTACT
H
Hayat Khizar, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here